AAAAAA

   
Results: 1-25 | 26-50 | 51-51
Results: 26-50/51

Authors: DEJONG RS WILLEMSE PHB BOONSTRA H DEVRIES EGE VANDERGRAAF WTA SLEIJFER DT VANDERZEE AGJ MULDER NH
Citation: Rs. Dejong et al., PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER, European journal of cancer, 31A(5), 1995, pp. 709-713

Authors: VELDHUIS GJ WILLEMSE PHB GROENEWEGEN A SLEIJFER DT VANDERGRAAF WTA MULDER NH DEVRIES EGE
Citation: Gj. Veldhuis et al., COMBINATION OF RHIL-6 AND GM-CSF IN PATIENTS BEFORE AND AFTER CHEMOTHERAPY (CT), European journal of cancer, 31A, 1995, pp. 230-230

Authors: DEVRIES EGE VANDERGRAAF WTA FRANSSEN E MULDER NH
Citation: Ege. Devries et al., CIRCUMVENTION OF MDR - ALTERNATIVES TO THE AFFLUX PUMP, European journal of cancer, 31A, 1995, pp. 303-303

Authors: VELDHUIS GJ WILLEMSE PHB VANDERGRAAF WTA AALDERS JG GROENEWEGEN A DEVRIES EGE
Citation: Gj. Veldhuis et al., RHIL-3 AND G-CSF VS G-CSF ALONE AFTER TAXOL-IFOSFAMIDE-CISPLATIN (TIC) CHEMOTHERAPY (CT) IN RESIDUAL PROGRESSIVE OVARIAN-CANCER (OC), European journal of cancer, 31A, 1995, pp. 516-516

Authors: WYMENGA ANM VANDERGRAAF WTA TIMENS W SPIJKERVET FKL DEVRIES EGE MULDER NH
Citation: Anm. Wymenga et al., STUDIES ON VITALITY OF ORAL EPITHELIAL-CELLS DURING AND AFTER HIGH-DOSE CHEMOTHERAPY - A NEW ASSAY FOR QUANTITATION OF CHEMOTHERAPY-INDUCEDMUCOSITIS, European journal of cancer, 31A, 1995, pp. 1209-1209

Authors: VANDERGRAAF WTA ZIJLSTRA JG DEVRIES EGE NETHERSELL ABW MULDER NH
Citation: Wta. Vandergraaf et al., IN-VITRO AND IN-VIVO STUDIES ON THE ACTION OF BW502U83, AN ARYLMETHYLAMINOPROPANEDIOL, Anti-cancer drugs, 6(1), 1995, pp. 34-39

Authors: VELDHUIS GJ WILLEMSE PHB SLEIJFER DT VANDERGRAAF WTA GROEN HJM LIMBURG PC MULDER NH DEVRIES EGE
Citation: Gj. Veldhuis et al., TOXICITY AND EFFICACY OF ESCALATING DOSAGES OF RECOMBINANT HUMAN INTERLEUKIN-6 AFTER CHEMOTHERAPY IN PATIENTS WITH BREAST-CANCER OR NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 13(10), 1995, pp. 2585-2593

Authors: SCHRODER CP VANDERGRAAF WTA KEMA IP GROENEWEGEN A SLEIJFER DT DEVRIES EGE
Citation: Cp. Schroder et al., SEROTONIN METABOLISM FOLLOWING PLATINUM-BASED CHEMOTHERAPY COMBINED WITH THE SEROTONIN TYPE-3 ANTAGONIST TROPISETRON, Cancer chemotherapy and pharmacology, 36(6), 1995, pp. 477-482

Authors: VANDERGRAAF WTA MULDER NH MEIJER C DEVRIES EGE
Citation: Wta. Vandergraaf et al., THE ROLE OF METHOXYMORPHOLINO ANTHRACYCLINE AND CYANOMORPHOLINO ANTHRACYCLINE IN A SENSITIVE SMALL-CELL LUNG-CANCER CELL-LINE AND ITS MULTIDRUG-RESISTANT BUT P-GLYCOPROTEIN-NEGATIVE AND CISPLATIN-RESISTANT COUNTERPARTS, Cancer chemotherapy and pharmacology, 35(4), 1995, pp. 345-348

Authors: DEGRAAF H MULDER NH WILLEMSE PHB VANDERGRAAF WTA SLEIJFER DT ZIJLSTRA JG ELIAS M SIBINGA CTS VELLENGA E DEVRIES EGE
Citation: H. Degraaf et al., THE ADDITIVE EFFECT OF PERIPHERAL-BLOOD STEM-CELLS, HARVESTED WITH LOW-DOSE CYCLOPHOSPHAMIDE, TO AUTOLOGOUS BONE-MARROW REINFUSION ON HEMATOPOIETIC RECONSTITUTION AFTER ABLATIVE CHEMOTHERAPY IN BREAST-CANCER PATIENTS WITH LOCALIZED DISEASE, Anticancer research, 15(6B), 1995, pp. 2851-2856

Authors: PLUKKER JTHM SLEIJFER DT VERSCHUEREN RCJ VANDERGRAAF WTA MULDER NH
Citation: Jthm. Plukker et al., NEOADJUVANT CHEMOTHERAPY WITH CARBOPLATIN, 4-EPIADRIAMYCIN AND TENIPOSIDE (CET) IN LOCALLY ADVANCED CANCER OF THE CARDIA AND THE LOWER ESOPHAGUS - A PHASE-II STUDY, Anticancer research, 15(5), 1995, pp. 2357-2361

Authors: MULDER NH DOLSMA WV MULDER POM DEVRIES EGE WILLEMSE PHB SLEIJFER DT HOSPERS GAP VANDERGRAAF WTA
Citation: Nh. Mulder et al., LONG-TERM RESULTS OF INDUCTION-CHEMOTHERAPY AND INTENSIFICATION CHEMOTHERAPY SUPPORTED WITH AUTOLOGOUS BONE-MARROW REINFUSION IN PATIENTS WITH DISSEMINATED OR T4 BREAST-CANCER, Anticancer research, 15(4), 1995, pp. 1565-1568

Authors: SLEIJFER S VANDERGRAAF WTA WILLEMSE PHB DEVRIES EGE KOOPS HS MULDER NH
Citation: S. Sleijfer et al., HIGH-DOSE METHOTREXATE, VINCRISTINE AND CISPLATIN AS SALVAGE TREATMENT FOR RELAPSED NONSEMINOMATOUS GERM-CELL CANCER, Anticancer research, 15(3), 1995, pp. 1039-1042

Authors: BUTER J SINNIGE HAM SLEIJFER DT DEVRIES EGE WILLEMSE PHB VANDERGRAAF WTA VERSCHUEREN RCJ MULDER NH
Citation: J. Buter et al., 5-FLUOROURACIL LEUCOVORIN INTERFERON ALPHA-2-ALPHA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER, Cancer, 75(5), 1995, pp. 1072-1076

Authors: GIETEMA JA VELDHUIS GJ GUCHELAAR HJ WILLEMSE PHB UGES DRA CATS A BOONSTRA H VANDERGRAAF WTA SLEIJFER DT DEVRIES EGE MULDER NH
Citation: Ja. Gietema et al., PHASE-II AND PHARMACOKINETIC STUDY OF LOBAPLATIN IN PATIENTS WITH RELAPSED OVARIAN-CANCER, British Journal of Cancer, 71(6), 1995, pp. 1302-1307

Authors: DEGRAAF H WILLEMSE PHB DEVRIES EGE SLEIJFER DT MULDER POM VANDERGRAAF WTA SIBINGA TS VANDERPLOEG E DOLSMA WV MULDER NH
Citation: H. Degraaf et al., INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSFUSION AS PRIMARY-TREATMENT IN WOMEN WITH BREAST-CANCER AND MORE THAN 5 INVOLVED AXILLARY LYMPH-NODES, European journal of cancer, 30A(2), 1994, pp. 150-153

Authors: VANDERGRAAF WTA BUTER J DEVRIES EGE WILLEMSE PHB SLEIJFER DT MULDER NH
Citation: Wta. Vandergraaf et al., HIGH-DOSE ORAL AMIODARONE ADDED TO DOXORUBICIN AND VINDESINE FOR OVERCOMING MULTIDRUG-RESISTANCE IN SOLID TUMORS, Annals of oncology, 5(7), 1994, pp. 659-660

Authors: DEGRAAF H WILLEMSE PHB SLEIJFER DT DEVRIES EGE VANDERGRAAF WTA BEUKEMA J MULDER NH
Citation: H. Degraaf et al., EFFECTIVE CONDITIONING REGIMEN FOR PREMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER, Anticancer research, 14(6B), 1994, pp. 2799-2804

Authors: BUTER J SLEIJFER DT WILLEMSE PHB VANDERGRAAF WTA DEVRIES EGE KOOPS HS MULDER NH
Citation: J. Buter et al., DOSE-ESCALATION OF DACARBAZINE COMBINED WITH INTERFERON ALPHA-2A, G-CSF AND ONDANSETRON IN PATIENTS WITH METASTATIC MELANOMA, Anticancer research, 14(3B), 1994, pp. 1325-1328

Authors: ELSINGA PH FRANSSEN EJF VANDERGRAAF WTA DEVRIES EGE VISSER GM VAALBURG W
Citation: Ph. Elsinga et al., C-11 LABELED DAUNORUBICIN - A TRACER FOR THE IN-VIVO INVESTIGATION OFMULTI DRUG-RESISTANCE, The Journal of nuclear medicine, 35(5), 1994, pp. 160000083-160000083

Authors: VANDERGRAAF WTA DEVRIES EGE TIMMERBOSSCHA H MEERSMA GJ MESANDER G VELLENGA E MULDER NH
Citation: Wta. Vandergraaf et al., EFFECTS OF AMIODARONE, CYCLOSPORINE-A, AND PSC-833 ON THE CYTOTOXICITY OF MITOXANTRONE, DOXORUBICIN, AND VINCRISTINE IN NON-P-GLYCOPROTEIN HUMAN SMALL-CELL LUNG-CANCER CELL-LINES, Cancer research, 54(20), 1994, pp. 5368-5373

Authors: KROESEN BJ BUTER J SLEIJFER DT JANSSEN RAJ VANDERGRAAF WTA THE TH DELEIJ L MULDER NH
Citation: Bj. Kroesen et al., PHASE-I STUDY OF INTRAVENOUSLY APPLIED BISPECIFIC ANTIBODY IN RENAL-CELL CANCER-PATIENTS RECEIVING SUBCUTANEOUS INTERLEUKIN-2, British Journal of Cancer, 70(4), 1994, pp. 652-661

Authors: MULDER NH VANDERGRAAF WTA WILLEMSE PHB KOOPS HS DEVRIES EGE SLEIJFER DT
Citation: Nh. Mulder et al., DACARBAZINE (DTIC)-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY OF PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA, British Journal of Cancer, 70(4), 1994, pp. 681-683

Authors: VANDERGRAAF WTA HAAXMAREICHE H BURGHOUTS JTM POSTMUS PE
Citation: Wta. Vandergraaf et al., TENIPOSIDE FOR MENINGEAL CARCINOMATOSIS OF SMALL-CELL LUNG-CANCER, Lung cancer, 10(3-4), 1993, pp. 247-249

Authors: BUTER J SLEIJFER DT VANDERGRAAF WTA DEVRIES EGE WILLEMSE PHB MULDER NH
Citation: J. Buter et al., A PROGRESS REPORT ON THE OUTPATIENT TREATMENT OF PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA USING SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2, Seminars in oncology, 20(6), 1993, pp. 16-21
Risultati: 1-25 | 26-50 | 51-51